The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
MJFF Research Grant, 2012The Role of Amyloid in the Progression of Cognitive Impairment in PD: A Prospective Cohort Study
Objective/Rationale:
Dementia is a frequent and devastating non-motor complication of Parkinson's disease (PD). Although loss of dopamine producing brain cells play a role in cognitive... -
Target Validation, 2012Evaluation of the Microtubule-Stabilizing Agent, Epothilone D, in Mouse Models of Parkinson's Disease
Objective/Rationale:
Microtubules are critical components within nerve cells, where they serve as the “railroad” tracks upon which cellular cargo is transported up and down the length of... -
Rapid Response Innovation Awards, 2013Neuromelanin in Circulating Phagocytes May Reveal Early Neurodegeneration in Parkinson’s Disease
Objective/Rationale:
A normal function of inflammation is to recruit phagocytic white blood cells (think PACMAN) to clear away the damaged cells. We postulate that debris laden PACMEN re... -
Therapeutic Pipeline Program, 2013Pre-clinical Evaluation of Neuroprotective Small Molecule Erythropoietin Receptor Agonists in the Treatment of Parkinson’s Disease
Objective/Rationale:
Erythropoietin (EPO) receptor is present throughout the body and plays a role in both red blood cell production and tissue protection. STATegics has discovered small... -
MJFF Research Grant, 2013Predicting Parkinson’s Disease with Smartphone Data
Objective/Rationale:
The purpose of The Michael J. Fox Foundation’s Parkinson’s Data Challenge was to develop a way to help patients and clinicians using objective, passively collected... -
Rapid Response Innovation Awards, 2013Discovery of EEG Biomarkers for Parkinson's Disease and Lewy Body Dementia
Objective/Rationale:
We aim to develop a non-invasive, low-cost pre-clinical biomarker for synucleinopathies such as Parkinson’s disease (PD) or Lewy body dementia (LBD), which will have...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.